EGFR and esophageal squamous cell carcinoma: In a phase 2 study, a chimeric EGFR mAb in combination with serplulimab and chemotherapy as a first-line therapy for advanced ESCC showed encouraging efficacy and manageable safety (Liu et al., 2024).